eligibility_summary
Eligible: 18–75, consent, untreated CD20+ DLBCL, IPI 2–5, ECOG 0–2, after 1 cycle Pola‑R‑CHP with ctDNA LFC<3, life ≥6 mo, LVEF ≥50%, adequate counts. Exclude: drug contraindications, prior transplant, select lymphoma subtypes, other malignancy unless low‑risk/curatively treated, major CVD, CNS disease, significant ECG, active/recent infection, uncontrolled autoimmune, abnormal labs, TB, HBsAg+ or HCV RNA+, PML, pregnancy, other uncontrolled conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 2, previously untreated CD20+ DLBCL. Arms: Pola‑RCHP (polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, prednisone) vs Pola‑RCHP‑X (same backbone plus genotype‑guided acalabrutinib or lenalidomide or decitabine). Drug types/mechanisms: Polatuzumab vedotin—antibody‑drug conjugate to CD79b delivering MMAE microtubule poison, rituximab—anti‑CD20 monoclonal antibody mediating ADCC/complement and apoptosis, cyclophosphamide—alkylating agent (DNA crosslinks), doxorubicin—anthracycline/topoisomerase II inhibitor, prednisone—glucocorticoid inducing lymphoid apoptosis. Add‑ons: acalabrutinib—covalent BTK inhibitor blocking BCR signaling, lenalidomide—IMiD via cereblon (degrades IKZF1/3), enhances T/NK activity, anti‑angiogenic, decitabine—hypomethylating DNMT‑inhibiting nucleoside analog. Targets/pathways: CD79b, CD20, BCR/BTK, microtubules, DNA damage (crosslinking/topo II), glucocorticoid signaling, DNA methylation, immune ADCC/T‑ and NK‑cell activation.